DDInter1938 DDInter1228
Vincristine is a vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer. It has a role as a tubulin modulator, a microtubule-destabilising agent, a plant metabolite, an antineoplastic agent and a drug. It is a methyl ester, an acetate ester, a tertiary alcohol, a member of formamides, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a tertiary amino compound and a vinca alkaloid. It is a conjugate base of a vincristine(2+). It derives from a hydride of a vincaleukoblastine.
Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. Mipomersen is indicated in patients with homozygous familial hypercholesterolemia as an adjunct to diet and other lipid-lowering medications. It is marketed under the brand name Kynamro in the United States, and the FDA label includes a black box warning of hepatoxicity. Specifically, elevations in the liver enzymes, i.e. transaminases, and in liver fat (hepatic steatosis) have been reported. Due to this serious risk of liver toxicity, mipomersen sodium is only available to patients under the restricted program called Kynamro Risk Evaluation and Mitigation Strategy program.
Vincristine {u} (Compound) upregulates {v} (Gene) EPHA2
EPHA2 {u} (Gene) is bound by {v} (Compound) Regorafenib
Regorafenib {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Vincristine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Regorafenib
Regorafenib {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Vincristine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Diclofenac
Diclofenac {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Vincristine {u} (Compound) upregulates {v} (Gene) EPHA2
EPHA2 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Vemurafenib {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Vincristine {u} (Compound) upregulates {v} (Gene) EPHA2
EPHA2 {u} (Gene) is upregulated by {v} (Compound) Clofarabine
Clofarabine {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Vincristine {u} (Compound) causes {v} (Side Effect) Myocardial infarction
Myocardial infarction {u} (Side Effect) is caused by {v} (Compound) Regorafenib
Regorafenib {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Vincristine {u} (Compound) causes {v} (Side Effect) Myocardial infarction
Myocardial infarction {u} (Side Effect) is caused by {v} (Compound) Diclofenac
Diclofenac {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Vincristine {u} (Compound) upregulates {v} (Gene) EPHA2
EPHA2 {u} (Gene) is bound by {v} (Compound) Nilotinib
Nilotinib {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Vincristine {u} (Compound) upregulates {v} (Gene) PRKAG2
PRKAG2 {u} (Gene) is upregulated by {v} (Compound) Stanozolol
Stanozolol {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Vincristine {u} (Compound) downregulates {v} (Gene) CEBPA
CEBPA {u} (Gene) is upregulated by {v} (Compound) Stanozolol
Stanozolol {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Vincristine (Compound) upregulates EPHA2 (Gene) and EPHA2 (Gene) is bound by Regorafenib (Compound) and Regorafenib may lead to a major life threatening interaction when taken with Mipomersen
Vincristine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Regorafenib (Compound) and Regorafenib may lead to a major life threatening interaction when taken with Mipomersen
Vincristine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Diclofenac (Compound) and Diclofenac may lead to a major life threatening interaction when taken with Mipomersen
Vincristine (Compound) upregulates EPHA2 (Gene) and EPHA2 (Gene) is downregulated by Vemurafenib (Compound) and Vemurafenib may lead to a major life threatening interaction when taken with Mipomersen
Vincristine (Compound) upregulates EPHA2 (Gene) and EPHA2 (Gene) is upregulated by Clofarabine (Compound) and Clofarabine may lead to a major life threatening interaction when taken with Mipomersen
Vincristine (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Regorafenib (Compound) and Regorafenib may lead to a major life threatening interaction when taken with Mipomersen
Vincristine (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Diclofenac (Compound) and Diclofenac may lead to a major life threatening interaction when taken with Mipomersen
Vincristine (Compound) upregulates EPHA2 (Gene) and EPHA2 (Gene) is bound by Nilotinib (Compound) and Nilotinib may lead to a major life threatening interaction when taken with Mipomersen
Vincristine (Compound) upregulates PRKAG2 (Gene) and PRKAG2 (Gene) is upregulated by Stanozolol (Compound) and Stanozolol may lead to a major life threatening interaction when taken with Mipomersen
Vincristine (Compound) downregulates CEBPA (Gene) and CEBPA (Gene) is upregulated by Stanozolol (Compound) and Stanozolol may lead to a major life threatening interaction when taken with Mipomersen